Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518594 · ClinicalTrials.gov registry record · Phase 3
A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
A Phase 3 study, sponsored by The George Washington University Biostatistics Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,311
- Enrollment target
NCT02518594: Completed Phase 3 study, sponsored by The George Washington University Biostatistics Center.
NCT02518594 is a Phase 3 study that has completed, run by The George Washington University Biostatistics Center. The registered enrollment target is 1,311 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02518594, a Phase 3 study, has completed, sponsored by The George Washington University Biostatistics Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,311 participants
- Enrollment target
Study Summary
This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.
Primary Outcome
Number of Participants who had preterm delivery or fetal loss of either twin prior to 35 weeks gestation
Interventions
- DRUG Placebo
- DRUG Vaginal progesterone
- DEVICE Arabin Pessary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,311 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 3 |
What the finished NCT02518594 record still lists
NCT02518594 is an interventional study that assigns participants to a tested intervention. Its 1,311 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02518594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02518594 about?
NCT02518594 is a clinical study titled "A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix". This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.
What is the current status of trial NCT02518594?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,311 participants. The study started on 2015-11-13. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT02518594?
The interventions under investigation include: Placebo (DRUG), Vaginal progesterone (DRUG), Arabin Pessary (DEVICE).
Who is sponsoring clinical trial NCT02518594?
This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02518594's enrollment target sits among peer trials
1,311 187th of 2000 higher than 1,814 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI